What question did this study set out to answer?

To highlight the severe bleeding risk associated with acquired factor V inhibitors in patients on triple antithrombotic therapy.

March 28, 2026Open Access

Acquired factor V inhibitor masked by triple antithrombotic therapy presenting as severe gastrointestinal bleeding: a case report

Puntos clave

To highlight the severe bleeding risk associated with acquired factor V inhibitors in patients on triple antithrombotic therapy.
Detailed case report of a 77-year-old male
Analysis of laboratory findings for coagulation parameters
Implementation of immunosuppressive therapy and CRRT for management
Patient presented with severe gastrointestinal bleeding
Acquired factor V deficiency identified due to factor V inhibitors
Successful treatment including transfusions and CRRT led to symptom resolution

Resumen

We report the case of a 77-year-old male with a history of coronary artery disease, on long-term dual antiplatelet therapy (DAPT) and edoxaban anticoagulation, who presented with severe gastrointestinal bleeding. Laboratory investigations revealed a profound acquired factor V deficiency due to the presence of factor V inhibitors. The patient was successfully treated with transfusion support, immunosuppressive therapy, and continuous renal replacement therapy (CRRT) for fluid management, leading to resolution of symptoms and normalization of coagulation parameters.

Me gusta

Guardar

Ver artículo completo